Evidence map›Paper›PMID 30804991›Full record

ArticleNeural plasticity2019

Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus.

Silvia Poggini, Maria Teresa Golia, Silvia Alboni, Giampaolo Milior, Livio Pepè Sciarria, Aurelia Viglione, Gloria Matte Bon, Nicoletta Brunello, Stefano Puglisi-Allegra, Cristina Limatola and 2 more

Open access · goldAbstract read
In one paragraph

Article in Neural plasticity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. A Pathophysiological Intersection of Diabetes and Alzheimer's Disease.International journal of molecular sciences · 2022
    Review
  8. Article
  9. The Role of Smad2 in Adult Neuroplasticity as Seen through Hippocampal-Dependent Spatial Learning/Memory and Neurogenesis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Silvia PogginiCenter for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.
Maria Teresa GoliaDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Rome, Italy.
Silvia AlboniDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Giampaolo MiliorDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Rome, Italy.
Livio Pepè SciarriaDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Rome, Italy.
Aurelia ViglioneCenter for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.
Gloria Matte BonCenter for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.
Nicoletta BrunelloDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Stefano Puglisi-AllegraDepartment of Psychology, Sapienza University of Rome, Rome, Italy.
Cristina LimatolaDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Rome, Italy.
Laura MaggiDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Rome, Italy.
Igor BranchiCenter for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0003-4484-3598
Istituto Pasteur · ITIstituto Superiore di Sanità · ITUniversity of Modena and Reggio Emilia · ITCentre National de la Recherche Scientifique · FRFondazione Santa Lucia · ITIstituto Neurologico Mediterraneo · ITScuola Normale Superiore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available.

Indexed as

AnhedoniaAnimalsAntidepressive AgentsDepressive DisorderDisease Models, AnimalDrug Therapy, CombinationFluoxetineHippocampusHypoglycemic AgentsInsulin-Like Growth Factor IIMaleMetforminMiceSelective Serotonin Reuptake InhibitorsAntidepressive AgentsFluoxetineHypoglycemic AgentsInsulin-Like Growth Factor IIMetforminSelective Serotonin Reuptake Inhibitors

Identifiers

PMID30804991
PMCPMC6360645
OpenAlexW2908827463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.